Pharmacology/Pharmaceutical Industry
WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial Due to Safety Concerns
26 May, 2020 | 09:35h | UTCSee also: WHO halts hydroxychloroquine trial for coronavirus amid safety fears – The Guardian AND WHO Halts Hydroxychloroquine Trial Over Safety Concerns – NPR
Remdesivir for the Treatment of Covid-19 — Preliminary Report
25 May, 2020 | 02:06h | UTCRemdesivir for the Treatment of Covid-19 — Preliminary Report – New England Journal of Medicine
Commentaries: Preliminary report on NIAID trial of remdesivir – PulmCrit AND Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery – National Institutes of Health AND Covid-19 study details benefits of treatment with remdesivir, and also its limitations – STAT
Related Commentary on Twitter (Thread – Click for more)
I finished reading the Remdesivir trial
If you want my thoughts you will have to read this thread
[Thread] pic.twitter.com/GqA30lCOLI
— Vinay Prasad (@VPrasadMDMPH) May 23, 2020
Perspective: The World May Be Overestimating the Power of Vaccines
25 May, 2020 | 01:55h | UTCThe world needs Covid-19 vaccines. It may also be overestimating their power – STAT
Hydroxychloroquine and Chloroquine for Covid-19: Large Observational Analysis Finds No Benefit and Possible Harm
25 May, 2020 | 02:03h | UTCCommentaries: Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? – The Lancet AND What a big new study on malaria drugs as Covid-19 treatments tells us — and what it doesn’t – STAT AND Hydroxychloroquine May Cause More Harm Than Benefit To COVID-19 Patients, Says New Lancet Study – Health Policy Watch
Opinion: Why Countries Should Stop Using Anti-malarial Drugs for COVID-19
25 May, 2020 | 02:02h | UTCWhy countries should stop using anti-malarial drugs for COVID-19 – The Conversation
Editorial – SARS-CoV2 Vaccines: Slow is Fast
25 May, 2020 | 01:54h | UTCSARS-CoV2 vaccines: Slow is fast – Science
Promising Early Results with New Vaccine from China in Phase I Trial
25 May, 2020 | 01:57h | UTCCommentaries: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response – The Lancet AND Early Study Of Covid-19 Vaccine Developed In China Sees Mixed Results – Forbes AND Coronavirus Vaccine Shows Promising Early Results in China – The New York Times AND A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials – Business Insider AND Experts skeptical after researchers report positive vaccine results – CNN AND Two COVID-19 Vaccine Candidates Induce Immune Response In Healthy Volunteers – Health Policy Watch
[Abstract Only] Randomized Trial: Haloperidol Effective for the Treatment of Headache in the Emergency Department
25 May, 2020 | 01:33h | UTC
Cohort Study: Fluconazole Use in the First Trimester of Pregnancy Linked to Increased Risk of Musculoskeletal Malformations
25 May, 2020 | 01:31h | UTCCommentary: Musculoskeletal Malformations Up With Fluconazole in Pregnancy – Physician’s Weekly
15 Drugs Being Tested to Treat COVID-19 and How They Would Work
22 May, 2020 | 04:52h | UTC15 drugs being tested to treat COVID-19 and how they would work – Nature
[Preprint] IL6 Inhibition in Critically Ill COVID-19 Patients is Associated with Increased Secondary Infections
22 May, 2020 | 04:44h | UTC
SARS-CoV-2 Infection Protects Against Rechallenge in Rhesus Macaques
21 May, 2020 | 09:27h | UTCSARS-CoV-2 infection protects against rechallenge in rhesus macaques – Science
Related Study: DNA vaccine protection against SARS-CoV-2 in rhesus macaques – Science
Commentaries: Infection With SARS-CoV-2 Protects Against Re-infection – At Least in Rhesus Macaques – Technology Networks AND Prototype Vaccine Protects Monkeys From Coronavirus – The New York Times
Systematic Review: Safety and Adverse Effects of 80 Antidepressants, Antipsychotics, Anti‐attention‐deficit/hyperactivity Medications and Mood Stabilizers in Children and Adolescents
21 May, 2020 | 09:10h | UTC
Editorial: Lack of Efficacy of Hydroxychloroquine in Covid-19
20 May, 2020 | 10:01h | UTCLack of efficacy of hydroxychloroquine in covid-19 – The BMJ
Original Research: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial – The BMJ
Related Meta-analysis (preprint) Hydroxychloroquine in COVID-19: A systematic review and meta-analysis – medRxiv
Meta-Analysis: ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19
20 May, 2020 | 09:50h | UTCRelated Study (Preprint): Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19 – medRxiv
Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody
19 May, 2020 | 04:35h | UTCCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody – Nature
Commentary: Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody – News Medical
Early Data Show Moderna Covid-19 Vaccine Generates Immune Response
19 May, 2020 | 04:29h | UTCEarly data show Moderna Covid-19 vaccine generates immune response – STAT
See also: Moderna Coronavirus Vaccine Trial Shows Promising Early Results – The New York Times AND Expert reaction to Moderna announcement about their phase 1 trial data on their mRNA vaccine (mRNA-1273) candidate against COVID-19 – Science Media Centre
Randomized Trial: No Benefit from Hydroxychloroquine in Patients with Mild to Moderate Covid-19
18 May, 2020 | 02:11h | UTCCommentary: Further evidence does not support hydroxychloroquine for patients with COVID-19 – BMJ
Systematic Review: Risks and Impact of ACE Inhibitors or ARBs on SARS-CoV-2 Infection in Adults
18 May, 2020 | 01:47h | UTC
Study: Use of Renin–angiotensin–aldosterone System Inhibitors Does Not Increase the Risk of COVID-19 Requiring Admission to Hospital
18 May, 2020 | 01:45h | UTCCommentary: Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19 – The Lancet
[Abstract Only] Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
15 May, 2020 | 03:22h | UTC
[Abstract Only] Randomized Trial: Improved Overall Survival with Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
15 May, 2020 | 03:23h | UTCSee also: Visual Abstract
[Abstract Only] Cost–benefit Analysis of Cancer Drugs in the USA and Europe
14 May, 2020 | 02:25h | UTCPrices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries: High cost of cancer drugs not always justified – University of Zurich AND High Cost of Cancer Drugs Does Not Reflect Clinical Benefit – Medscape
Study Commentary – Virus Wars: Return of Lopinavir/Ritonavir (Along with Ribavirin and Interferon)
13 May, 2020 | 02:12h | UTCVirus Wars: Return of Lopinavir/Ritonavir (along with ribavirin and interferon) – PulmCrit
Original Article: Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial (study and commentaries)
Hydroxychloroquine in Patients with COVID-19: A Systematic Review and Meta-analysis
13 May, 2020 | 01:53h | UTC“While initial studies with hydroxychloroquine showed some ray of hope, recent studies that have emerged found either no benefit or a possible harm in COVID-19.”